The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment
Featured:
Robert ZeiserThe GvHD Hub was pleased to speak with Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE, about the mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in chronic graft-versus-host disease (cGvHD) treatment.
Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment
Zeiser begins by providing an overview of cGvHD and its implications for patients. This is followed by a discussion on three recently approved drugs, ibrutinib, ruxolitinib, and belumosudil, including their mechanisms of action in relation to cGvHD (Figure 1). Finally, Zeiser summarizes the clinical activity and recent trials investigating these drugs.
Figure 1. The mechanisms of action of ibrutinib, belumosudil, and ruxolitinib, and their treatment effects in cGvHD*
BCR, B-cell receptor; cGvHD, chronic graft-versus-host disease; ECM, extracellular matrix; IFN, interferon; IL, interleukin; TCR, T-cell receptor; Th17 cells, T helper 17 cells; T reg cells, regulatory T cells.
*Adapted from Zeiser et al.1
References